{"id":"NCT03264157","sponsor":"Bio Products Laboratory","briefTitle":"Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects","officialTitle":"A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-12-08","primaryCompletion":"2018-03-02","completion":"2018-07-13","firstPosted":"2017-08-29","resultsPosted":"2020-02-11","lastUpdate":"2020-02-25"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Healthy"],"interventions":[{"type":"DRUG","name":"HRIG","otherNames":[]},{"type":"DRUG","name":"HyperRAB","otherNames":["HRIG"]},{"type":"BIOLOGICAL","name":"RabAvert","otherNames":["active rabies vaccine"]}],"arms":[{"label":"BPL HRIG + RabAvert","type":"EXPERIMENTAL"},{"label":"Comparator HyperRab + RabAvert","type":"ACTIVE_COMPARATOR"}],"summary":"A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.","primaryOutcome":{"measure":"Proportion of Subjects With Anti-rabies Antibody Titer of â‰¥0.5 IU/mL","timeFrame":"Day 14","effectByArm":[{"arm":"BPL HRIG + RabAvert","deltaMin":73,"sd":null},{"arm":"Comparator HyperRab + RabAvert","deltaMin":72,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":81},"commonTop":["Headache","Upper respiratory tract infection","Vaccination site pain"]}}